Detailed explanation of contraindications and drug risks for patients with Everolimus (Afinitor)

Everolimus is a mTOR inhibitor and is mainly used for the treatment of kidney cancer, breast cancer and the prevention of organ transplant rejection. During use, pregnant and lactating women are strictly prohibited from taking it to avoid potential toxicity to the fetus or infant. At the same time, patients who are allergic to everolimus or drug excipients should also avoid taking it to avoid serious allergic reactions.

Everolimus will suppress the function of the immune system, so patients with active infections or severely immunocompromised patients should not use it, otherwise it may easily lead to aggravation of infection or the occurrence of opportunistic infections. In clinical practice, patients taking everolimus for a long time need to regularly monitor their blood and infection indicators. Once fever, cough or other infection symptoms occur, they should seek medical treatment immediately.

Everolimus is metabolized in the liver, so patients with severe liver function impairment should use it with caution or adjust the dose; at the same time, patients with renal insufficiency may also increase the risk of drug accumulation and need to be used under the guidance of a doctor. For patients with previous hepatitis, cirrhosis or chronic kidney disease, liver and kidney function should be assessed before use and reviewed regularly during medication to reduce drug toxicity and adverse reactions.

Everolimus has significant drug interactions with certainCYP3A4 inhibitors or inducers, which may cause abnormal increases or decreases in blood concentration, thereby increasing side effects or reducing efficacy. Therefore, patients should inform their doctors about all the medications they are taking, including Chinese herbal medicines and health supplements. At the same time, blood pressure, blood sugar, blood lipids and lung function need to be monitored regularly to prevent risks such as pulmonary toxicity and metabolic abnormalities.

Reference materials:https://www.drugs.com/